StreetAlpha.app
Home › Stocks › CTNM

Contineum Therapeutics, Inc. (CTNM)

Healthcare
$9.55
▼ −1.24%
LAST CLOSE · NOV 17

Contineum Therapeutics develops small molecule drugs for lung fibrosis, chronic pain, depression and multiple sclerosis. It last closed at $9.55 on Nov 17, down 1.24% on the day. The average 12-month price target from 3 analysts is $20.33 (+112.9% from the last close), with a high of $30.00 and a low of $14.00. Analyst consensus is Hold, based on the latest ratings from 3 firms (1 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in CTNM, 100% of them bullish and 0% bearish.

AI Auto Pilots
Is CTNM in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$63.5M
EPS (diluted)
−$1.77
Free cash flow
−$52.2M
Balance sheet
Cash & equivalents
$75.2M
At Sep 30
Shareholder equity
$245.4M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $22.7M$22.7MFY2023FY2024: −$42.3M−$42.3MFY2024FY2025: −$60.0M−$60.0MFY2025

From CTNM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Hold
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Hold
3firms
1 Buy2 Hold0 Sell
Each firm's latest rating on CTNM in the past 90 days
Average 12-month target
$20.33
▲ 112.9% upside

Based on 3 analysts who set a price target on CTNM in the past 90 days. The average target is $20.33, with a high of $30.00 and a low of $14.00, compared with the last close of $9.55.

Low $14.00Avg $20.33High $30.00
Blue marker: last close $9.55
Highest target$30.00
Average target$20.33
Lowest target$14.00
Latest rating changes
Jones TradingTarget raised
Oct 15Buy$24 → $30
BairdDowngrade
Oct 14Hold$19 → $14
Morgan StanleyMaintained
Sep 28Hold$17
Jones TradingMaintained
Sep 15Buy$24
BairdMaintained
Sep 15Buy$19
DateFirmActionRatingPrice target
Oct 15Jones TradingTarget raisedBuy$24 → $30
Oct 14BairdDowngradeHold$19 → $14
Sep 28Morgan StanleyMaintainedHold$17
Sep 15Jones TradingMaintainedBuy$24
Sep 15BairdMaintainedBuy$19
Loading…

Technical Analysis

CTNM · as of the Nov 17 close · updated after every close
Moving sideways

The stock sits between its 20 and 50 day averages. It is 40% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 46). The nearest support is the Pivot at $9.52, and the nearest resistance the Pivot R1 at $9.71.

Short trendNeutral
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 8.7%/day
Key levels
$17.7952 week high+86.3%
$13.35200 day average+39.8%
$13.20100 day average+38.2%
$11.0150 day average+15.3%
$10.90Swing high (Nov 11)+14.1%
$9.71Pivot R1+1.7%
$9.55Last close
$9.52Pivot−0.3%
$9.4020 day average−1.6%
$9.36Pivot S1−2.0%
$8.59Swing low (Nov 6)−10.1%
$6.7352 week low−29.5%
Indicators
RSI (14)45.83Middle of its rangeNeutral
MACD-0.22Above its signal lineBullish
Stochastic50.6Middle of its rangeNeutral
ADX (14)21.4Weak trend
Williams %R-58.5Oversold below −80, overbought above −20Neutral
CCI (20)16.8Oversold below −100, overbought above 100Neutral
Rate of change−1.4%Change over 10 sessionsBearish
ATR (14)$0.83Typical daily range, 8.7% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for CTNM

What happened before

See how CTNM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Oct 28 – Oct 28
Loading…

See today’s whale options flow across the market →

CTNM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲71 buying vs 38 selling
  • ▲Held by funds +16.6 pts
  • ▲Funds holding +17
  • ▼Superinvestors: 0 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding119102+16.7%
In funds' top 10440.0%
Held by funds148.9%132.3%+16.6 pts
New / increased28 / 4328 / 32+18.3%
Reduced / sold out27 / 1119 / 15+11.8%
Put/call ratio0.25––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CTNM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CTNM is in one of them and how their past CTNM trades turned out.

CTNM in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CTNM in an article yet. Here's the latest on the wider market.

About Contineum Therapeutics

Contineum Therapeutics is a San Diego, California company developing small molecule drugs for neuroscience and immunology conditions. Its lead candidate, PIPE-791, is being developed as a pill taken once a day for idiopathic pulmonary fibrosis and is also being studied for chronic pain. A second candidate, PIPE-307, is being developed for depression and multiple sclerosis in partnership with Johnson & Johnson. The company's drugs are intended for patients with these conditions, and none are approved for sale yet.

Headquarters
San Diego, CA